Lebrikizumab gets the nod for treating moderate-to-severe atopic dermatitis in Europe
Lebrikizumab, an interleukin-13 inhibitor, is not yet approved in the United States.
MDedge News
source https://www.medscape.com/s/viewarticle/998647?src=rss
MDedge News
source https://www.medscape.com/s/viewarticle/998647?src=rss
Comments
Post a Comment